



# DURECT Corporation to Participate in the ROTH Capital Partners Healthcare Event “Covid-19 Therapeutics in Development”

CUPERTINO, Calif., Oct. 26, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will participate in the ROTH Capital Healthcare Event, “Covid-19 Therapeutics in Development,” taking place on Wednesday, October 28, 2020. The ROTH Healthcare and Biotechnology team are hosting the webinar to discuss key therapies in development to treat COVID disease.

The Webinar includes three sessions: “Immune Modulators to Ameliorate COVID Disease 1,” “Direct Antivirals and Other Agents Against SARS-CoV2 Virus,” and “Indirect Antivirals Against SARS-CoV2 Virus.”

To register for the event, please click [here](#).

## Wednesday, October 28<sup>th</sup> @ 10:30am - 11:50am Eastern Time

Session Title: Direct Antivirals and Other Agents Against SARS-CoV2 Virus  
Participants: Tarek Hassanein, M.D., F.A.C.P., F.A.C.G., A.G.A.F., F.A.A.S.L.D., Professor of Medicine at University of California San Diego School of Medicine  
Durect Corporation (DRRX)  
Aridis Pharmaceuticals (ARDS)  
Hepion Pharmaceuticals (HEPA)  
CohBar Inc (CWBR)  
Beyond Air (XAIR)

## About DURECT Corporation

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DURECT's lead candidate, DUR-928 is an endogenous sulfated oxysterol and an epigenetic regulator. It represents a new class of therapeutics with a unique mechanism of action. DUR-928 epigenetically modulates the expression of multiple clusters of master genes that are involved in many important cell signaling pathways, through which it stabilizes mitochondria, reduces lipotoxicity, regulates inflammatory or stress responses, and promotes cell survival. This drug candidate is in Phase 2 development for the treatment of alcoholic hepatitis (AH) and the treatment of COVID-19 patients with acute liver or kidney injury as well as Phase 1 development for the treatment of nonalcoholic steatohepatitis (NASH). DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR<sup>A</sup>® (bupivacaine sustained-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. For more information about DURECT, please visit [www.durect.com](http://www.durect.com) and follow us on Twitter <https://twitter.com/DURECTCorp>.

## DURECT Forward-Looking Statement

The statements in this press release regarding clinical development plans for DUR-928, including the potential use of DUR-928 to treat COVID-19 patients with liver or kidney injury, the potential use of DUR-928 to treat acute organ injuries, such as AH, and chronic liver diseases, such as NASH, the life saving potential of DUR-928, and the potential use of POSIMIR to provide pain relief after surgery are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that the clinical trial of DUR-928 in COVID-19 patients is delayed or stopped because of changes to the standard of care, the availability of alternative therapies, protocol changes or lack of available patients, the risk that future clinical trials of DUR-928 are not started when anticipated, take longer to conduct than anticipated, do not confirm the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy or the life saving potential of DUR-928 in a statistically significant manner, the risk that the FDA will not approve POSIMIR or approve POSIMIR with a limited label, the risk that additional time and resources may be required for development, testing and regulatory approval of DUR-928 or the Company's other product candidates, potential adverse effects



arising from the testing or use of our drug candidates, our potential failure to maintain our collaborative agreements with third parties and risks related to our ability to obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on August 4, 2020 under the heading "Risk Factors."

NOTE: POSIMIR<sup>®</sup> and SABER<sup>®</sup> are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. DUR-928 and POSIMIR are investigational drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication.



View original content: [http://www.prnewswire.com/news-releases/direct-corporation-to-participate-in-the-roth-capital-](http://www.prnewswire.com/news-releases/direct-corporation-to-participate-in-the-roth-capital-partners-healthcare-event-covid-19-therapeutics-in-development-301159876.html)

[partners-healthcare-event-covid-19-therapeutics-in-development-301159876.html](http://www.prnewswire.com/news-releases/direct-corporation-to-participate-in-the-roth-capital-partners-healthcare-event-covid-19-therapeutics-in-development-301159876.html)

SOURCE DURECT Corporation

Corporate Contact: Mike Arenberg, DURECT, Chief Financial Officer, +1-408-346-1052, [mike.arenberg@durect.com](mailto:mike.arenberg@durect.com); Media Contact: Alison Chen, LifeSci Communications, +1-646-876-4932, [achen@lifescicomms.com](mailto:achen@lifescicomms.com)